NCT02290210View on ClinicalTrials.gov

Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

July 24, 2014

Primary Completion Date

December 2, 2014

Study Completion Date

August 31, 2015

Conditions

GoutHyperuricemia

Interventions

DRUG

URC102 0.25mg

DRUG

URC102 0.5mg

DRUG

URC102 1.0mg

DRUG

URC102 2.0mg

DRUG

placebo

Trial Locations (1)

137-864

JW Pharmaceutical, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY